Biosimilars Pricing In Medicare Part D Needs Legislative Fix, Avalere Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Requiring 50% discount for biosimilars in the coverage gap or establishing biosimilar specialty tier with reduced coinsurance could encourage broader take-up, consulting firm suggests.
You may also be interested in...
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.